Genetic conditions associated with predisposition to HLH
. | Selected mechanism(s) of HLH predisposition . |
---|---|
Familial HLH | |
PRF1 | Defective lymphocyte granule–mediated cytotoxicity |
UNC13D | Defective lymphocyte granule–mediated cytotoxicity |
STX11 | Defective lymphocyte granule–mediated cytotoxicity |
STXBP2 | Defective lymphocyte granule–mediated cytotoxicity |
Pigmentary disorders associated with HLH | |
RAB27A | Defective lymphocyte granule–mediated cytotoxicity |
LYST | Defective lymphocyte granule–mediated cytotoxicity |
AP3B1 | Defective lymphocyte granule–mediated cytotoxicity |
XLP-1 and XLP-2 | |
SH2D1A | Defective 2B4-mediated cytotoxicity; defective T-cell restimulation–induced cell death; absent iNKT cells |
XIAP | Dysregulated NLRP3 inflammasome function; increased effector cell susceptibility to cell death |
NLRC4 | Constitutively active NLRC4 inflammasome function |
CDC42 | Defective formation of actin-based structures; defective proliferation, migration, and cytotoxicity; increased IL-1β and Il-18 production |
EBV susceptibility disorders | |
MAGT1 | Defective Mg++ transporter; low NKG2D, defective cytotoxicity |
ITK | Defective tyrosine kinase function; defective cytotoxic T-cell expansion and cytolytic capacity; decreased iNKT cells |
CD27 | CD27 expressed on T cells participates in costimulatory signaling, interacts with CD70; required for normal T-cell proliferation and triggering of cytotoxicity against EBV-infected B cells; decreased iNKT cells |
CD70 | CD70 expressed by EBV-infected B cells interacts with CD27 on T cells; required for normal expansion and cytotoxicity of the T cells; decreased NKG2D, 2B4; decreased iNKT cells |
CTPS1 | Enzyme involved in de novo synthesis of cytidine nucleotide triphosphate (CTP) (critical precursor of nucleic acid metabolism); deficiency leads to impaired proliferation; decreased iNKT cells |
RASGRP1 | Activates RAS, which leads to MAPK pathway activation; defects in T-cell activation, proliferation, and migration; decreased cytotoxicity; decreased iNKT cells |
. | Selected mechanism(s) of HLH predisposition . |
---|---|
Familial HLH | |
PRF1 | Defective lymphocyte granule–mediated cytotoxicity |
UNC13D | Defective lymphocyte granule–mediated cytotoxicity |
STX11 | Defective lymphocyte granule–mediated cytotoxicity |
STXBP2 | Defective lymphocyte granule–mediated cytotoxicity |
Pigmentary disorders associated with HLH | |
RAB27A | Defective lymphocyte granule–mediated cytotoxicity |
LYST | Defective lymphocyte granule–mediated cytotoxicity |
AP3B1 | Defective lymphocyte granule–mediated cytotoxicity |
XLP-1 and XLP-2 | |
SH2D1A | Defective 2B4-mediated cytotoxicity; defective T-cell restimulation–induced cell death; absent iNKT cells |
XIAP | Dysregulated NLRP3 inflammasome function; increased effector cell susceptibility to cell death |
NLRC4 | Constitutively active NLRC4 inflammasome function |
CDC42 | Defective formation of actin-based structures; defective proliferation, migration, and cytotoxicity; increased IL-1β and Il-18 production |
EBV susceptibility disorders | |
MAGT1 | Defective Mg++ transporter; low NKG2D, defective cytotoxicity |
ITK | Defective tyrosine kinase function; defective cytotoxic T-cell expansion and cytolytic capacity; decreased iNKT cells |
CD27 | CD27 expressed on T cells participates in costimulatory signaling, interacts with CD70; required for normal T-cell proliferation and triggering of cytotoxicity against EBV-infected B cells; decreased iNKT cells |
CD70 | CD70 expressed by EBV-infected B cells interacts with CD27 on T cells; required for normal expansion and cytotoxicity of the T cells; decreased NKG2D, 2B4; decreased iNKT cells |
CTPS1 | Enzyme involved in de novo synthesis of cytidine nucleotide triphosphate (CTP) (critical precursor of nucleic acid metabolism); deficiency leads to impaired proliferation; decreased iNKT cells |
RASGRP1 | Activates RAS, which leads to MAPK pathway activation; defects in T-cell activation, proliferation, and migration; decreased cytotoxicity; decreased iNKT cells |